Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:33 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 289–312 of 8,143 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Oral Clear all
Recruiting Phase 1Phase 2 Interventional

Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma

NCT03161223
View directory record Official record
Conditions
Lymphoma, T-Cell
Interventions
Durvalumab, Pralatrexate, Romidepsin, 5-Azacitidine
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

NCT00046462
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 11, 2011 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BIIB100 Administered Orally to Adults With Amyotrophic Lateral Sclerosis

NCT03945279
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
BIIB100, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
9
States / cities
Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2023 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Vitamin D Supplementation on Oral Glucose Tolerance Among Obese Adolescents

NCT01856946
View directory record Official record
Conditions
Insulin Resistance
Interventions
4,000 IU vitamin D3
Dietary Supplement
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
9 Years to 19 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 10, 2016 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Understand the Effect of a Study Medicine Called ARV-471 on Rosuvastatin in Healthy Adults

NCT05652660
View directory record Official record
Conditions
Healthy
Interventions
ARV-471, Rosuvastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 2 Interventional

Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole

NCT00005920
View directory record Official record
Conditions
Candidiasis, Oral, HIV Infections
Interventions
L-743,872
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rahway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 5:33 AM EDT
Withdrawn No phase listed Observational

Non-Invasive Oral Biofilm Characterization

NCT02178046
View directory record Official record
Conditions
Gingivitis
Interventions
optical measurements
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Nov 1, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Dental Hygiene and Peri-Implant Tissues Homeostasis

NCT03384446
View directory record Official record
Conditions
Peri-Implantitis
Interventions
Tooth-borne treatment, Implant-specific treatment
Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years and older
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2023
U.S. locations
2
States / cities
San Antonio, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 5, 2023 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors

NCT01340846
View directory record Official record
Conditions
Cancer
Interventions
Warfarin, Ketoconazole, Gemfibrozil, GSK2118436 150mg, GSK2118436 75mg
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
8
States / cities
Scottsdale, Arizona • Sarasota, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

NCT00410124
View directory record Official record
Conditions
Metastatic Renal Cell Carcinoma
Interventions
RAD001, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
31
States / cities
Fayetteville, Arkansas • Duarte, California • Sacramento, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2013 · Synced Oct 22, 2026, 5:33 AM EDT
Active, not recruiting Not applicable Interventional

Effect of Whitening Agent With Emulsion Gel in Saliva and Halitosis

NCT06194123
View directory record Official record
Conditions
Xerostomia, Halitosis
Interventions
Crest Daily Whitening Serum
Other
Lead sponsor
Tufts University
Other
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2026 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Study of Tarceva and Targretin Oral Capsules in Patients With Advanced Lung Cancer

NCT00125359
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
erlotinib and bexarotene
Drug
Lead sponsor
Konstantin Dragnev
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
2
States / cities
Lebanon, New Hampshire • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional Results available

12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)

NCT02107196
View directory record Official record
Conditions
Irritable Bowel Syndrome With Diarrhea
Interventions
Ibodutant 10 mg, Placebo
Drug
Lead sponsor
Menarini Group
Industry
Eligibility
18 Years and older · Female only
Enrollment
535 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
65
States / cities
Huntsville, Alabama • Sherwood, Arizona • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 3 Interventional

A Multicenter VESIcare® Efficacy and Safety Study for the Treatment of Urgency Associated With Overactive Bladder (OAB)

NCT00454896
View directory record Official record
Conditions
Urinary Bladder, Overactive
Interventions
VESIcare®, placebo
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
739 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
65
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Atherton, California + 60 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Sofusa System With Sumatriptan (KC5010) Phase 1 Dose Escalation Safety and PK Study (KCC-SMT-002)

NCT03229798
View directory record Official record
Conditions
Migraine Disorders
Interventions
Sumatriptan Succinate Oral Tablet, Transdermal delivery of sumatriptan succinate
Drug · Combination Product
Lead sponsor
Sorrento Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effect of Black Raspberry Phytochemicals on Oral Microbiome in Current Smokers and Non-smokers

NCT02439255
View directory record Official record
Conditions
Healthy Subject, Tobacco Use Disorder
Interventions
Laboratory Biomarker Analysis, Phytochemical, Placebo, Screening Questionnaire Administration
Other · Dietary Supplement
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 50 Years
Enrollment
148 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Oct 22, 2026, 5:33 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Find a Suitable Dose of ASP8731 and Check for Medical Problems at Each Dose in Healthy Adults

NCT05167526
View directory record Official record
Conditions
Healthy Participants
Interventions
ASP8731, ASP8731 Matching Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 22, 2026, 5:33 AM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task

NCT04778644
View directory record Official record
Conditions
CBD
Interventions
CBD, Placebo
Drug
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 12, 2024 · Synced Oct 22, 2026, 5:33 AM EDT
Not listed Phase 3 Interventional

NB-001 Treatment of Recurrent Herpes Labialis

NCT01695187
View directory record Official record
Conditions
Herpes Labialis
Interventions
NB-001 (0.3%), Placebo
Drug
Lead sponsor
NanoBio Corporation
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
12
States / cities
Chandler, Arizona • Tucson, Arizona • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2013 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 2 Interventional Results available

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687
View directory record Official record
Conditions
Smoking, Marijuana
Interventions
CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lexington, Kentucky • New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2019 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Relative Bioavailability Study for GSK1278863A

NCT01319006
View directory record Official record
Conditions
Anaemia
Interventions
GSK1278863A
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Phase 1 Interventional

A Study to Determine the Safety and Efficacy of LX3305 in Subjects With Active Rheumatoid Arthritis

NCT01417052
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
50 mg LX3305 QD, 100 mg LX3305 QD, 150 mg LX3305 QD, 200 mg LX3305 QD, 250 mg LX3305 QD, 300 mg LX3305 QD, 400 mg LX3305 QD, 250 mg LX3305 BID, 500 mg LX3305 QD, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 22, 2026, 5:33 AM EDT
Completed Not applicable Interventional

Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)

NCT00002026
View directory record Official record
Conditions
Leukoplakia, Hairy, HIV Infections
Interventions
Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 22, 2026, 5:33 AM EDT